Equity neuroscience最新文献

{"title":"Incidence of pediatric chronic tic disorders and feasibility of using the Massachusetts All-Payer Claims Database, 2012-2016.","authors":"Marisela E Dy-Hollins, Mamoon Habib, Erika F Augustine, Elyse R Park, Vicki Fung, Alexander C Tsai, Lidia M V R Moura","doi":"10.1016/j.neuros.2026.100028","DOIUrl":"10.1016/j.neuros.2026.100028","url":null,"abstract":"<p><strong>Background: </strong>Nearly 1.5 million children in the United States have a chronic tic disorder, an under-recognized childhood-onset complex chronic condition characterized by involuntary movements and/or sounds, that is often comorbid with neuropsychiatric illness. This study sought to examine the feasibility of using the Massachusetts All-Payer Claims Database to identify incident cases of chronic tic disorders.</p><p><strong>Methods: </strong>In this retrospective analysis using the 2012-2016 Massachusetts All-Payer Claims Database, participants 4-18 years of age with health insurance for at least one year between 1/1/2013-12/31/2016 were included. Incident tic disorder diagnosis was defined as the first observed ICD-9/ICD-10 code for tic disorders with no diagnosis claim in the prior 12 months (e.g., Tourette Syndrome: 307.23, F95.2). Age at diagnostic encounter, sex, and insurance type were examined for those with an incident tic diagnosis.</p><p><strong>Results: </strong>Between 2012-2016, there were 1,638,691 unique claims for individuals aged 4-18 years. Of these, 1,258 unique claims had an incident tic disorder diagnosis. The mean age (± standard deviation) at diagnostic encounter was 9.7±3.5 years. Participants were predominantly male (74.5%) and had Medicaid coverage (64.8%).</p><p><strong>Conclusions: </strong>The Massachusetts All-Payer Claims Database is feasible to examine the incidence of chronic tic disorders in a pediatric population. Future studies will examine access to and quality of care in chronic tic disorders.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13175131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147966975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The importance of health equity research for all populations in the United States: SEQUINS hall of fame lecture.","authors":"Lewis B Morgenstern, Nancy G Ramirez","doi":"10.1016/j.neuros.2026.100027","DOIUrl":"10.1016/j.neuros.2026.100027","url":null,"abstract":"<p><strong>Background: </strong>Health equity research has recently been criticized by both liberals and conservatives in the U.S. This research holds potential to serve all U.S. populations by examining mechanisms of resilience. Resilience may broadly be defined as the development of the ability to withstand adversity that leads to the prevention or recovery from disease.</p><p><strong>Purpose: </strong>This is an invited paper stemming from a Society for Equity Neuroscience (SEQUINS) inaugural Hall of Fame lecture in May of 2025.</p><p><strong>Methods: </strong>The authors use research focused on Mexican Americans in the Brain Attack Surveillance in Corpus Christi (BASIC) project to illustrate how health equity research may be informative for all U.S. populations. BASIC is a community-based project with strong collaborations in the community.</p><p><strong>Results: </strong>Over the 25 years of BASIC's existence, the stroke disparity among Mexican Americans and non-Hispanic White Americans has largely vanished with respect to incidence, recurrence, and outcome (neurologic, functional, and cognitive). This suggests that resilience mechanisms among Mexican Americans have improved stroke health outcomes. Using a framework suggested by Taylor and colleagues, the authors propose that these resilience mechanisms may help all Americans regardless of race and ethnicity.</p><p><strong>Conclusions: </strong>Studying resilience offers a novel, hopeful aspect to health equity research that may demonstrate benefits across the U.S. Still, resilience implies the need to suffer first. Improving health outcomes by removing barriers and ensuring adequate healthcare for all Americans should be the goal. Health equity researchers should work closely with communities to design and conduct projects that are important to that community.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13166142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147937335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging equity: Why vascular neurologists need routine ultrasound training.","authors":"Ali Zahir, Bruce Ovbiagele","doi":"10.1016/j.neuros.2026.100050","DOIUrl":"10.1016/j.neuros.2026.100050","url":null,"abstract":"<p><p>Stroke disparities persist globally and are driven in part by diagnostic delays and uneven access to advanced neuroimaging. Cerebrovascular ultrasound offers a portable, bedside modality that can optimize stroke evaluation across diverse clinical environments, yet formal training in its use remains inconsistent. This perspective argues that structured, competency-based ultrasound education within vascular neurology fellowships represents a practical, equity-aligned intervention to address diagnostic gaps. While training alone cannot resolve structural drivers of inequity, standardizing ultrasound proficiency can equip clinicians with adaptable diagnostic skills, support timely decision-making, and promote more equitable stroke care delivery across practice settings.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13170299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global DNA methylation and MTHFR gene polymorphism status of ghanaians with early-onset intracerebral hemorrhage: implications for future interventions.","authors":"Priscilla Abrafi Opare-Addo, Fred Stephen Sarfo, Bruce Ovbiagele, Minas Aikins, Serwaa Asare-Bediako, Richard Boateng, Oscar Simon Olympio Mensah, Adwoa Agyemang Adu-Gyamfi, Nessya Taylor, Maxwell Nyenaah, Samuel Kekeli Agordzo, Emmanuella Naa Ayerki Nartey, Christian Obirikorang, Francis Agyemang-Yeboah","doi":"10.1016/j.neuros.2026.100058","DOIUrl":"10.1016/j.neuros.2026.100058","url":null,"abstract":"<p><strong>Background: </strong>Contrary to global trends, the incidence of intracerebral hemorrhage (ICH) in Sub-Saharan Africa is on a relentless rise, with a relatively early age of onset. While studies among Africans have largely focused on traditional risk determinants, global evidence indicates that genetic and epigenetic variations substantially impact ICH risk.</p><p><strong>Aim: </strong>This study aimed to determine the association between MTHFR C677T polymorphisms and ICH risk among Ghanaians with ICH onset at age ≤ 50 years and to compare global DNA methylation levels.</p><p><strong>Methods: </strong>We conducted a case-control study among 164 ICH cases and 164 matched controls. Genotyping was by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP), and quality was ensured by including positive and negative controls, with a 100% recall rate. Further validation was through in-silico analysis using National Center for Biotechnology Information (NCBI) reference sequences (https://bit.ly/4kB2KBT). Genotype distribution was categorized as CC = homozygous wild-type, CT = heterozygous, and TT = homozygous variant. Global DNA methylation status was measured using the ab117128 Methylated DNA Quantification Kit.</p><p><strong>Results: </strong>The frequency of the CC genotype was 100%, while the CT and TT genotypes were absent in both ICH cases and controls. This limited further assessment of associations. Global DNA methylation status was found to be significantly higher in ICH cases (2.62 ng) compared to controls (2.48 ng), <i>p</i> = 0.030.</p><p><strong>Conclusions: </strong>In this Ghanaian cohort, no meaningful evaluation of the association between the MTHFR C677T polymorphism and ICH risk was possible due to its monomorphic distribution. However, increased global DNA methylation in ICH cases compared to controls suggests a potential role of epigenetic mechanisms in the pathophysiology of early-onset ICH, with possible prospects for risk mitigation, particularly in this nutritionally vulnerable population. Further genome- and epigenome-wide association studies are warranted in this population.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and predictors of disease progression in parkinson's disease in a cohort of patients in the ashanti region, Ghana.","authors":"Vida Obese, Berrnard Nkum, John Akassi, Manolo Agbenorku, Sheila Adamu, Priscilla Abrafi Opare-Addo, Andrew Jacobs Bilson, Hanson Ababio, Mie Rizig, Fred Stephen Sarfo","doi":"10.1016/j.neuros.2026.100051","DOIUrl":"10.1016/j.neuros.2026.100051","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is a progressive neurodegenerative disorder with motor and non-motor symptoms. Sub-Saharan Africa (SSA) with its rapidly rising ageing population is experiencing a surge in the burden of PD in clinical care. Delayed diagnosis and treatment initiation, coupled with socioeconomic and healthcare barriers, may uniquely contribute to the population of PD with advanced clinical disease in SSA. This study aimed to clinically characterize Ghanaian PD patients, and identify predictors of mid-to-advanced disease.</p><p><strong>Methods: </strong>A hospital-based cross-sectional study was conducted at Komfo Anokye Teaching Hospital, Ghana (May 2023 - March 2024). Consecutive adults meeting UK Brain Bank criteria for PD diagnosis were neurologist-confirmed and evaluated using structured interviews including Hoehn and Yahr (H&Y) staging, and MDS-UPDRS. Data were analyzed using Graph Pad Prism, with logistic regression identifying predictors of mid-to-advanced PD defined by H&Y stages 3-5.</p><p><strong>Results: </strong>Of 161 participants (mean age 64.0 ± 9.1 years; 114 males), 98 (60.9%) were in early-stage PD (H&Y stages 1-2). Mid-to-advanced stages (H&Y stages 3-5) had higher motor scores (19.9 vs 15.4; <i>p</i> = 0.003) but lower non-motor scores (<i>p</i> < 0.001). Medication use was universal in mid-to-advanced stages vs 42.9% in early stages (<i>p</i> = 0.001). Male patients, those who had lost employment due to PD, and those with moderate UPDRS severity were more likely to have mid-to-advanced disease, whereas higher income and urinary symptoms were less likely.</p><p><strong>Conclusion: </strong>Mixes of socio-demographic and clinical features are associated with mid-to-advanced stages of PD among this Ghanaian sample of PD patients. Integrating socioeconomic determinants into prognostic models may enable earlier identification of patients with mid-to-advanced PD and guide targeted interventions such as social support systems to improve their quality of life in resource-limited settings.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13233050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148166830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke minimization through additive anti-atherosclerotic agents in routine treatment (SMAART) II: Rationale for a multi-country polypill phase 3 trial in sub-Saharan Africa.","authors":"Fred Stephen Sarfo, Kolawole Wahab, Sarah Shali Matuja, Philip Babatunde Adebayo, Thierry Adoukonou, Raelle Tagge, Bruce Ovbiagele","doi":"10.1016/j.neuros.2026.100020","DOIUrl":"10.1016/j.neuros.2026.100020","url":null,"abstract":"<p><strong>Rationale: </strong>Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. Fixed-dose combination pills, also known as \"polypills\", containing generic drugs: Aspirin, a statin, and blood pressure (BP) lowering medications may be a viable low-cost avenue to broadly improve medication adherence and consequently reduce further disability or death on a large scale among stroke survivors in SSA.</p><p><strong>Objectives: </strong>The Stroke Minimization through Additive Anti-atherosclerotic agents in Routine Treatment II <i>(</i>SMAART-II<i>)</i> study seeks to deploy a hybrid study design to <i>1)</i> demonstrate the efficacy of a polypill (Polycap ^®) containing fixed doses of antihypertensives, a statin, and antiplatelet therapy taken as <i>two capsules</i>, once daily orally in reducing composite vascular risk over 24 months vs. usual care among 1000 recent ischemic stroke patients encountered at primary and tertiary hospitals in Benin, Nigeria and Tanzania; <i>2)</i> develop an implementation strategy for routine integration and policy adoption of polypill for post-stroke cardiovascular risk reduction in an under-resourced system burdened by suboptimal care and outcomes.</p><p><strong>Expected impact: </strong>SMAART II will establish the definitive efficacy and safety of the polypill to improve meaningful post-stroke global risk factor control across several sites, across diverse healthcare settings, beyond tertiary level care, and over a longer period. In addition to assessing clinical outcomes, SMAART II will assess implementation outcomes such as adoption, acceptability, cost, pertinent to uptake of the polypill strategy in the three proposed African countries to inform policy.</p><p><strong>Trial registration: </strong>NCT05963568.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12922694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147274291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthy eating index (HEI) and stroke: Population-level clinical evidence.","authors":"Jinpyo Hong, Manuel Bita, Alain Lekoubou, Djibril M Ba","doi":"10.1016/j.neuros.2025.100019","DOIUrl":"10.1016/j.neuros.2025.100019","url":null,"abstract":"","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12858096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finding community for early career health equity researchers.","authors":"Javier A Suarez, Kimberly A O'Neill, Jillian Berkman","doi":"10.1016/j.neuros.2025.100018","DOIUrl":"10.1016/j.neuros.2025.100018","url":null,"abstract":"<p><p>Health equity research in neurology and neuroscience faces a unique challenge in the current United States climate of funding scarcity and prioritization of other research topics. The low funding contrasts with rising interest and scholarship in the field. Neuroscientists in the early phases of their career are particularly vulnerable to the detrimental effects of reduced funding due to their relatively lower publication history and established sources of support for projects. Here, we introduce the Early Career Network within the Society of Equity Neuroscience (SEQUINS). The group is dedicated to the support of early-career neurologists and neuroscientists who pursue health equity neuroscience research. We will accomplish this via a combination of virtual and in-person events as well as the establishment of a robust community of scientists. Together, we will foster camaraderie, solidarity, and shared interests to propel the field of health equity neuroscience forward.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12857917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The significance of the WHO/ISH absolute cardiovascular risk prediction scores among recent stroke survivors in Ghana-Insights from the PINGS2 multicenter study.","authors":"Ansumana Bockarie, Nana Kwame Ayisi-Boateng, Samuel Blay Nguah, Lambert Tetteh Appiah, Sanaa Afriyie-Ansah, Evans MacCready, Victoria Aba Sam, Nathaniel Adusei Mensah, Raelle Tagge, Kwadwo Agyenim-Boateng, Micheal Ampofo, Ruth Laryea, Rexford Adu Gyamfi, John Humphrey Amuasi, Agnes Arthur, Christiana Neizer, Priscilla Opare-Addo, Bruce Ovbiagele, Fred Stephen Sarfo, Albert Akpalu","doi":"10.1016/j.neuros.2026.100024","DOIUrl":"10.1016/j.neuros.2026.100024","url":null,"abstract":"<p><strong>Background: </strong>The leading cause of stroke remains atherosclerotic cardiovascular disease. The World Health Organization/International Society of Hypertension risk score represents an effort to produce a risk assessment tool for atherosclerotic cardiovascular disease that is regionally specific. No previous work has described absolute cardiovascular risk scores among recent stroke survivors in West Africa via this tool.</p><p><strong>Methods: </strong>A cross-sectional analysis of baseline data from the multicenter, phase III randomized, open-label, clinical trial, Phone-based Intervention under Nurse Guidance II (PINGS-2), was performed. Data from 414 participants who had recently survived a stroke and met the age range compatible with the risk estimation tool were analyzed. The WHO/ISH score was calculated for each participant and categorized into low, moderate, and high/very high CVD risk scores. Demographic data, medical histories, anthropometry, vascular risk profiles, stroke types and severity indices were compared across CVD risk categories. Multivariate logistic regression was performed to further examine variables significantly associated with WHO/ISH CVD risk via univariate analysis.</p><p><strong>Results: </strong>The mean age of the study population was 58 years (SD = 12), with the majority being male (56.5%). Ischemic strokes (<i>n</i> = 268, 73.4%) were more common than hemorrhagic strokes (<i>n</i> = 84, 23%). Over two-thirds (76.3%) of the participants were estimated to have a low (<10%) risk of cardiovascular disease in the next 10 years, 14.5% were estimated to have a moderate risk, and only 9.2% were stratified as high or very high risk. The absolute CVD risk score was significantly associated with age, higher income, tobacco use, systolic blood pressure and HBA1c. There was no significant difference in absolute cardiovascular risk by stroke type.</p><p><strong>Conclusion: </strong>The majority of recent stroke survivors in this multicenter Ghanaian cohort were classified as having low absolute CVD risk. This raises questions about the performance of the WHO/ISH risk assessment tool in this population.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12987673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiologic profiling using plasma renin activity and aldosterone on blood pressure control among Ghanaian stroke survivors: A pilot trial.","authors":"Fred Stephen Sarfo, Priscilla Abrafi Opare-Addo, Manolo Agbenorku, Vida Obese, Sheila Adamu, Rexford Adu Gyamfi, John Akassi, Hanson Ababio, Michael Ampofo, Nathaniel Adusei Mensah, Gideon Acheampong, Bruce Ovbiagele","doi":"10.1016/j.neuros.2025.100013","DOIUrl":"10.1016/j.neuros.2025.100013","url":null,"abstract":"<p><strong>Background and purpose: </strong>Resistant hypertension (RH) is mechanistically driven largely by perturbations in renin-aldosterone, rife among stroke survivors, and portends a poorer prognosis in this population. We sought to evaluate the feasibility of a physiological profiling strategy using plasma renin and aldosterone to tailor medical therapy to control BP among stroke survivors with uncontrolled RH.</p><p><strong>Methods: </strong>This was a pilot randomized clinical trial. We enrolled stroke survivors aged ≥18 years with uncontrolled blood pressure on at least 3 antihypertensive medications at full doses at a tertiary hospital in Ghana. Participants were enrolled between June 16, 2023, and April 19, 2024, and the last participant completed follow-up on October 30, 2024. Participants randomized to the physiologic profiling arm had plasma renin activity and aldosterone levels measured and eplerenone, a mineralocorticoid receptor antagonist, or amiloride was added to their existing BP medications depending on renin-aldosterone profile. Those assigned to the control arm received usual care where physicians added antihypertensive agents as indicated. The primary clinical outcome was proportions with blood pressure < 140/90 mmHg at month 6, by intention-to-treat.</p><p><strong>Results: </strong>Among 60 eligible participants, 30 each were randomized to either the intervention or control arms, 53 % were female, mean (SD) age of 58.4 (10.3) years. The trial was feasible to implement. Primary outcome was achieved in 19 (63.3 %) in the intervention arm vs. 11 (36.7 %) in the usual care arm, p = 0.04. There were 3 major adverse cardiovascular events during follow-up, 1 (3.3 %) non-fatal recurrent stroke in the intervention arm vs 2 (6.7 %) cardiovascular deaths in the usual care arm, p = 0.55. No medication-related adverse events were reported.</p><p><strong>Conclusions: </strong>Among Ghanaian stroke survivors with RH, the addition of eplerenone to background antihypertensive medications based on plasma renin-aldosterone profile demonstrated a signal of efficacy compared with usual care. A larger study with longer follow-up powered to assess hard cardiovascular outcomes among stroke survivors with uncontrolled resistant hypertension is warranted.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12803734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}